Quimi Daphne's Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed May 16, 2024
- Accession no.
- 0000950170-24-061294
- Filed
- May 16, 2024
- Trade date
- May 14-15, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $9.45K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Quimi DaphneCIK 0001543031 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 14, 2024 | Common Stock | PPurchaseAcquired | +2,750 | $1.89 | +$5,197.5 | 2,750 | Direct | |
| May 15, 2024 | Common Stock | PPurchaseAcquired | +2,250 | $1.89 | +$4,252.5 | 5,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.